Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Phase 3 RCT with sustained, clinically meaningful weight loss and metabolic improvements over 76 weeks, but lacks active comparator and cardiovascular outcomes needed for practice-changing status.
A narrative expert review synthesizing current evidence on pharmacological HCC chemoprevention, identifying established approaches (antivirals, vaccination), agents with observational support (statins), and emerging candidates requiring prospective validation.